Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Margaret Macy

Concepts (237)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Neuroblastoma
14
2026
174
3.110
 Why?
Antineoplastic Combined Chemotherapy Protocols
15
2026
1953
1.570
 Why?
Neoplasms
19
2026
2875
1.420
 Why?
Central Nervous System Neoplasms
3
2024
173
1.330
 Why?
Neoplasm Recurrence, Local
14
2026
1137
1.230
 Why?
Sarcoma, Ewing
3
2025
102
1.140
 Why?
Protein Kinase Inhibitors
7
2025
969
0.840
 Why?
Cyclin-Dependent Kinase 4
1
2024
53
0.830
 Why?
Cyclin-Dependent Kinase 6
1
2024
49
0.830
 Why?
Central Nervous System Diseases
1
2024
74
0.770
 Why?
Neoplasms, Second Primary
1
2024
100
0.750
 Why?
Glioma
5
2025
425
0.750
 Why?
Antineoplastic Agents
12
2026
2194
0.740
 Why?
Drug Resistance, Neoplasm
8
2026
881
0.730
 Why?
Piperazines
1
2024
381
0.700
 Why?
Antibodies, Monoclonal, Humanized
5
2022
985
0.700
 Why?
Glycolipids
1
2021
52
0.680
 Why?
Child
45
2026
22633
0.630
 Why?
Pyridines
1
2024
605
0.620
 Why?
Radiation Injuries
2
2019
151
0.610
 Why?
Indazoles
2
2022
80
0.600
 Why?
Bevacizumab
2
2019
167
0.590
 Why?
Brain Stem Neoplasms
2
2017
87
0.580
 Why?
Astrocytoma
2
2017
129
0.570
 Why?
Benzamides
2
2022
224
0.570
 Why?
Radiotherapy
1
2019
206
0.560
 Why?
Child, Preschool
28
2026
11787
0.550
 Why?
Brain Diseases
1
2019
152
0.550
 Why?
Chemoradiotherapy
2
2017
237
0.540
 Why?
Receptor Protein-Tyrosine Kinases
2
2022
230
0.530
 Why?
Angiogenesis Inhibitors
1
2019
237
0.530
 Why?
Adolescent
33
2026
22428
0.470
 Why?
3-Iodobenzylguanidine
3
2025
12
0.470
 Why?
Prognosis
14
2026
4282
0.450
 Why?
Gangliosides
2
2025
23
0.410
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
2
2026
161
0.400
 Why?
Brain Neoplasms
5
2022
1318
0.390
 Why?
Sarcoma
2
2015
205
0.390
 Why?
Bridged Bicyclo Compounds, Heterocyclic
2
2026
279
0.390
 Why?
Rhabdomyosarcoma
2
2025
64
0.350
 Why?
Sulfonamides
2
2026
580
0.340
 Why?
Piperidines
2
2025
217
0.340
 Why?
Quinazolines
2
2023
266
0.330
 Why?
Neoplasms, Germ Cell and Embryonal
1
2012
75
0.330
 Why?
Topoisomerase II Inhibitors
1
2010
26
0.330
 Why?
Antineoplastic Agents, Immunological
2
2025
199
0.320
 Why?
Biomarkers, Tumor
4
2022
1313
0.320
 Why?
Humans
53
2026
144759
0.320
 Why?
Maximum Tolerated Dose
6
2025
212
0.320
 Why?
Follow-Up Studies
10
2026
5408
0.310
 Why?
Survival Rate
8
2026
2089
0.310
 Why?
Antibodies, Monoclonal
7
2026
1519
0.300
 Why?
Glioblastoma
1
2012
353
0.280
 Why?
Young Adult
15
2026
14105
0.280
 Why?
Leukemia
1
2010
245
0.280
 Why?
DNA Damage
1
2010
430
0.260
 Why?
Male
31
2026
72315
0.250
 Why?
Infant
14
2026
10034
0.250
 Why?
Female
31
2026
78271
0.240
 Why?
Leukemia, Myeloid, Acute
3
2025
682
0.240
 Why?
Trastuzumab
1
2026
118
0.230
 Why?
Medical Oncology
2
2024
332
0.230
 Why?
Infratentorial Neoplasms
1
2026
71
0.230
 Why?
Liver Neoplasms
1
2012
780
0.230
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
293
0.220
 Why?
Gene Expression Profiling
1
2012
1782
0.220
 Why?
Camptothecin
2
2017
140
0.220
 Why?
Cyclin D
1
2024
8
0.220
 Why?
Cyclin-Dependent Kinases
1
2025
123
0.210
 Why?
Glycogen Synthase Kinase 3 beta
1
2024
72
0.210
 Why?
TOR Serine-Threonine Kinases
3
2024
449
0.210
 Why?
Ependymoma
1
2026
176
0.210
 Why?
Dose-Response Relationship, Drug
5
2025
2027
0.210
 Why?
Neoplasm Staging
3
2024
1462
0.200
 Why?
Bone Neoplasms
2
2024
253
0.200
 Why?
Carcinoma, Non-Small-Cell Lung
2
2023
1180
0.200
 Why?
Sirolimus
2
2016
281
0.190
 Why?
Osteosarcoma
1
2023
76
0.180
 Why?
Oncogene Proteins, Fusion
1
2024
210
0.180
 Why?
Pediatrics
2
2020
1114
0.180
 Why?
High-Throughput Nucleotide Sequencing
2
2023
549
0.180
 Why?
Proto-Oncogene Proteins c-akt
1
2024
436
0.180
 Why?
Topotecan
3
2026
17
0.180
 Why?
Adult
17
2026
40449
0.180
 Why?
Central Nervous System
1
2024
281
0.170
 Why?
Phosphatidylinositol 3-Kinases
1
2023
380
0.170
 Why?
Whole Genome Sequencing
1
2021
182
0.160
 Why?
Salvage Therapy
2
2019
162
0.160
 Why?
Necrosis
2
2019
244
0.160
 Why?
Receptor, IGF Type 1
2
2010
64
0.150
 Why?
Pyridazines
1
2020
57
0.150
 Why?
Lung Neoplasms
2
2023
2637
0.150
 Why?
Etoposide
3
2017
166
0.140
 Why?
Dexamethasone
2
2019
372
0.140
 Why?
Imidazoles
1
2020
254
0.140
 Why?
Combined Modality Therapy
2
2020
1266
0.140
 Why?
Lymphoma
1
2019
232
0.140
 Why?
Taxoids
1
2018
116
0.130
 Why?
B7-H1 Antigen
1
2019
241
0.130
 Why?
Induction Chemotherapy
1
2017
87
0.130
 Why?
Heterocyclic Compounds
1
2017
23
0.130
 Why?
Antineoplastic Agents, Phytogenic
1
2018
177
0.130
 Why?
Incidence
1
2024
2879
0.130
 Why?
Cetuximab
1
2017
111
0.120
 Why?
Glucocorticoids
2
2019
535
0.120
 Why?
Azacitidine
1
2017
156
0.120
 Why?
Cytarabine
3
2025
66
0.120
 Why?
Hematopoietic Stem Cell Transplantation
1
2022
675
0.120
 Why?
Clinical Trials as Topic
3
2025
1053
0.120
 Why?
Myelodysplastic Syndromes
1
2017
147
0.110
 Why?
Retrospective Studies
6
2026
17066
0.110
 Why?
Cyclophosphamide
2
2026
266
0.110
 Why?
Feasibility Studies
1
2019
1095
0.110
 Why?
Treatment Outcome
9
2025
11679
0.110
 Why?
Thyroxine
1
2014
64
0.100
 Why?
Hypothyroidism
1
2014
67
0.100
 Why?
Pilot Projects
1
2019
1886
0.100
 Why?
Melanoma
1
2019
761
0.100
 Why?
Arsenicals
1
2013
28
0.100
 Why?
Oxides
1
2013
51
0.090
 Why?
Protein-Tyrosine Kinases
2
2022
433
0.090
 Why?
Organoplatinum Compounds
1
2012
66
0.090
 Why?
Leucovorin
1
2012
101
0.090
 Why?
In Situ Hybridization, Fluorescence
2
2012
322
0.090
 Why?
DNA Methylation
1
2017
681
0.090
 Why?
Animals
4
2021
38058
0.090
 Why?
Consensus
2
2025
488
0.090
 Why?
Fluorouracil
1
2012
235
0.090
 Why?
Real-Time Polymerase Chain Reaction
1
2012
341
0.090
 Why?
Spinal Cord
1
2014
380
0.080
 Why?
Magnetic Resonance Imaging
3
2019
3863
0.080
 Why?
HL-60 Cells
1
2010
29
0.080
 Why?
Inhibitory Concentration 50
1
2010
91
0.080
 Why?
Oligonucleotide Array Sequence Analysis
1
2012
758
0.080
 Why?
Antimetabolites, Antineoplastic
1
2010
105
0.080
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2012
983
0.080
 Why?
Pyrazoles
2
2025
509
0.080
 Why?
Drug Synergism
1
2010
357
0.080
 Why?
Pons
1
2009
33
0.080
 Why?
Methotrexate
1
2010
240
0.070
 Why?
Brain
2
2014
2933
0.070
 Why?
Vascular Endothelial Growth Factor A
2
2009
557
0.070
 Why?
Polyethylene Glycols
1
2014
654
0.070
 Why?
Infant, Newborn
3
2022
6429
0.070
 Why?
Recurrence
2
2010
1135
0.070
 Why?
Molecular Targeted Therapy
2
2022
432
0.070
 Why?
Chemistry, Pharmaceutical
1
2008
109
0.070
 Why?
Doxorubicin
1
2010
397
0.070
 Why?
Drug Design
1
2008
173
0.070
 Why?
Acute Disease
1
2010
1030
0.070
 Why?
Cell Cycle
1
2010
596
0.070
 Why?
Cell Survival
1
2010
1098
0.060
 Why?
Pyrimidines
2
2023
532
0.060
 Why?
MAP Kinase Signaling System
1
2008
310
0.060
 Why?
Injections, Spinal
1
2026
120
0.060
 Why?
Genomics
2
2022
834
0.060
 Why?
Risk Assessment
1
2015
3671
0.060
 Why?
Cohort Studies
3
2022
5960
0.060
 Why?
Everolimus
1
2025
111
0.050
 Why?
Proto-Oncogene Protein c-fli-1
1
2024
29
0.050
 Why?
RNA-Binding Protein EWS
1
2024
30
0.050
 Why?
United States Food and Drug Administration
1
2025
203
0.050
 Why?
Phenylurea Compounds
1
2025
112
0.050
 Why?
Disease Progression
1
2012
2847
0.050
 Why?
Europe
1
2025
412
0.050
 Why?
Immunoconjugates
1
2025
132
0.050
 Why?
RNA, Messenger
1
2012
2832
0.050
 Why?
Mice
1
2021
18339
0.050
 Why?
Quinolines
1
2025
193
0.050
 Why?
Vincristine
1
2024
140
0.050
 Why?
Radioisotopes
1
2023
33
0.050
 Why?
Lactams
1
2023
28
0.050
 Why?
Infusions, Intravenous
1
2024
423
0.050
 Why?
Cell Proliferation
1
2010
2496
0.050
 Why?
Lactams, Macrocyclic
1
2023
51
0.050
 Why?
Magnesium
1
2023
155
0.050
 Why?
National Cancer Institute (U.S.)
1
2022
52
0.050
 Why?
Gene Amplification
1
2023
120
0.050
 Why?
Aminopyridines
1
2023
127
0.050
 Why?
Oncogenes
1
2022
119
0.040
 Why?
Apoptosis
1
2010
2430
0.040
 Why?
Proto-Oncogene Proteins c-myc
1
2023
167
0.040
 Why?
Microtubule-Associated Proteins
1
2022
196
0.040
 Why?
Models, Biological
1
2008
1821
0.040
 Why?
Drug and Narcotic Control
1
2020
24
0.040
 Why?
Carcinogenesis
1
2022
229
0.040
 Why?
Drug Evaluation, Preclinical
1
2020
194
0.040
 Why?
Immunologic Factors
1
2022
255
0.040
 Why?
United States
3
2025
15966
0.040
 Why?
Fatigue
1
2022
366
0.040
 Why?
Proto-Oncogene Proteins
1
2022
623
0.040
 Why?
Base Sequence
1
2022
2190
0.040
 Why?
Disease Susceptibility
1
2020
348
0.040
 Why?
Retreatment
1
2018
77
0.040
 Why?
Isotretinoin
1
2018
26
0.030
 Why?
Metabolic Clearance Rate
1
2018
114
0.030
 Why?
Hematologic Diseases
1
2018
66
0.030
 Why?
Daunorubicin
1
2017
25
0.030
 Why?
Azepines
1
2018
107
0.030
 Why?
Precision Medicine
1
2021
457
0.030
 Why?
Benzylamines
1
2017
43
0.030
 Why?
Blepharoptosis
1
1997
12
0.030
 Why?
Genes, Dominant
1
1997
101
0.030
 Why?
Immunotherapy
1
2022
653
0.030
 Why?
Treatment Failure
1
2018
365
0.030
 Why?
Disease-Free Survival
1
2019
769
0.030
 Why?
Chromosomes, Human, Pair 1
1
1997
78
0.030
 Why?
Drug Hypersensitivity
1
2018
90
0.030
 Why?
Receptors, CXCR4
1
2017
91
0.030
 Why?
Gastrointestinal Diseases
1
2018
216
0.030
 Why?
Kaplan-Meier Estimate
1
2018
965
0.030
 Why?
Antibiotics, Antineoplastic
1
2016
139
0.030
 Why?
Drug Monitoring
1
2018
395
0.030
 Why?
SEER Program
1
2015
224
0.030
 Why?
Age Factors
1
2020
3333
0.020
 Why?
Genetic Predisposition to Disease
1
2021
2363
0.020
 Why?
Promoter Regions, Genetic
1
2017
1257
0.020
 Why?
Epigenesis, Genetic
1
2017
684
0.020
 Why?
Analysis of Variance
1
2015
1306
0.020
 Why?
Neoplasm Grading
1
2013
307
0.020
 Why?
Prevalence
1
2019
2834
0.020
 Why?
Mutation
1
2023
4089
0.020
 Why?
Radiography
1
2014
844
0.020
 Why?
Signal Transduction
1
2024
5226
0.020
 Why?
Prospective Studies
1
2022
7990
0.020
 Why?
Fatal Outcome
1
2009
307
0.020
 Why?
Tomography, X-Ray Computed
1
2018
2730
0.020
 Why?
Radiosurgery
1
2009
400
0.010
 Why?
Aged
1
2024
25913
0.010
 Why?
Middle Aged
1
2024
35875
0.010
 Why?
Lod Score
1
1997
62
0.010
 Why?
Quality of Life
1
2009
3185
0.010
 Why?
Genetic Markers
1
1997
331
0.010
 Why?
Recombination, Genetic
1
1997
205
0.010
 Why?
Chromosome Mapping
1
1997
510
0.010
 Why?
Pedigree
1
1997
514
0.010
 Why?
Genotype
1
1997
1833
0.010
 Why?
Macy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (237) concept(s)
_
Co-Authors Expand Description
See all (19) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)